Twitter

Novartis Invests in Next Generation Therapies to Reduce Cardiovascular Risk

Novartis (No. 2 on the DiversityInc Top 50 Companies list) has announced a collaboration and option agreement with Ionis Pharmaceuticals, Inc. and its affiliate Akcea Therapeutics, Inc., to license two novel treatments with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of lipoproteins known as Lp(a) and ApoCIII.


The two investigational antisense therapies developed by Ionis-called AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx-have the potential to lower both lipoproteins up to 90% and significantly reduce cardiovascular risk in high-risk patient populations. In addition Novartis entered into a stock purchase agreement with Ionis.

“Novartis is building a robust cardiovascular portfolio of targeted therapies to address unmet medical need of high-risk patients,” said Vasant Narasimhan, Global Head, Drug Development and Chief Medical Officer, Novartis. “Lp(a) and ApoCIII are potent, genetically validated cardiovascular risk reduction targets. The importance of predictive biomarkers in achieving successful cardiovascular outcomes will also be essential in the future payer environment. We look forward to working with Ionis and Akcea to develop both treatments.”

Novartis will be able to exercise its options to license and commercialize AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx following the achievement of specified development milestones and prior to the initiation of Phase 3 studies for each program. Upon in-licensing Novartis will be responsible for worldwide development and commercialization of both assets.

Ionis’ antisense technology is currently the most effective way to inhibit synthesis of both lipoproteins in the liver, according to data published in the Lancet[1]. The GalNAc3-conjugated antisense oligonucleotide technology is 30 times more potent than the parent antisense oligonucleotide, leading to a lower dose and the potential for highly effective therapeutic targeting and much improved tolerability.

The deal is subject to customary closing conditions and regulatory approvals.

About Atherosclerosis

Atherosclerosis is a disease in which plaque builds up inside the arteries leading to gradual narrowing and hardening of the arteries and increased risk of blood clots, heart attack and stroke. Atherosclerosis that affects the arteries of the heart is commonly known as coronary heart disease.

About Dyslipidemia

Dyslipidemia is the elevation of plasma cholesterol, triglycerides, or both, or a low high-density lipoprotein level that contributes to the development of atherosclerosis.

About Lipoprotein(a) (Lp(a))

Lp(a) is a lipoprotein that travels through the blood. Elevated levels of Lp(a) collect in the arteries, gradually narrowing the arteries and limiting blood supply to the heart, brain, kidneys and legs. This leads to increased risk of coronary heart disease, atherosclerosis, thrombosis and stroke. Additional information is available through Lipoprotein (a) Foundation at www.lipoproteinafoundation.org(link is external)

About Apolipoprotein-CIII (ApoCIII)

ApoCIII is a protein produced in the liver that plays a central role in the regulation of triglycerides, a type of fat found in the blood. People with elevated levels of ApoCIII have high triglycerides which are associated with multiple metabolic abnormalities such as insulin resistance and/or metabolic syndrome. People who do not produce ApoCIII have lower levels of triglycerides and lower instances of cardiovascular disease.

Latest News

AT&T on Celebrating Hispanic Heritage Month in 2021

Originally published at about.att.com by Thaddeus Arroyo, CEO of AT&T Consumer. AT&T is a DiversityInc Hall of Fame company.   This Hispanic Heritage Month, we are highlighting and celebrating what makes Hispanic stories so special. We will explore how the vast, diverse and evolving culture of the Hispanic community represents…

KeyBank’s Key4Women Program and SCORE Cleveland Announce Finalists for Women-Owned Business Pitch Contest in Ohio

Originally published at investor.key.com. KeyBank ranked No. 23 on The DiversityInc Top 50 Companies for Diversity list in 2021.   KeyBank’s Key4Women program and SCORE Cleveland today announced 10 finalists have been selected to compete in a business pitch contest for women-owned businesses (WOBs) located in Northeast Ohio. Selected from…

OneTen CEO Maurice Jones on Partnering With Wells Fargo To Rethink Talent and Open the Opportunity Pipeline

Originally published at stories.wf.com. Wells Fargo ranked No. 25 on The DiversityInc Top 50 Companies for Diversity list in 2021.   All Americans share an aspiration for economic opportunity, yet there is a persistent, intergenerational opportunity gap that prevents millions of Black individuals from having meaningful access to the American…

Johnson & Johnson Announces Global Call for Nominations for the 2022 Women in STEM2D (WiSTEM2D) Scholars Award

Originally published at jnj.com. Johnson & Johnson is a DiversityInc Hall of Fame company.   Johnson & Johnson announced it is accepting applications for its 2022 Women in STEM2D (WiSTEM2D) Scholars Award. The award, which aims to support assistant or associate academic professors in the disciplines of Science, Technology, Engineering,…